Addition of Erlotinib to Sorafenib Does Not Improve Survival in Advanced Liver Cancer
the Cancer Therapy Advisor take:
According to a new study published in the Journal of Clinical Oncology, researchers have found that the addition of erlotinib to sorafenib does not improve survival in patients with advanced hepatocellular carcinoma.
For the international, double-blind, placebo-controlled phase 3 study, researchers sought to determine whether adding erlotinib to sorafenib would improve clinical outcomes for patients with advanced hepatocellular carcinoma.
Researchers enrolled 720 patients with advanced hepatocellular carcinoma and underlying Child-Pugh class A liver cirrhosis and randomly assigned them to receive sorafenib plus either placebo or erlotinib. All patients had not received systemic treatment prior to the study.
Results showed that the median overall survivals were similar across both arms (9.5 months in the sorafenib plus erlotinib group versus 8.5 months in the sorafenib plus placebo group; HR = 0.929; P = 0.408). The median time to progression was also similar in both arms (3.2 months versus 4.0 months; HR = 1.135; P = 0.18).
The overall response rate was slightly higher in the sorafenib plus erlotinib arm (P = 0.102), but the disease control rate was significantly lower in that arm (P = 0.021). In regard to safety, adverse events were similar in both arms.
Addition of erlotinib to sorafenib does not improve survival in patients with advanced hepatocellular carcinoma.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival
- The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma
- FDA Approves Fulvestrant/Abemaciclib Combination for Breast Cancer
- Beta-blockers May Prevent Stress-induced Lung Cancer Treatment Resistance
- Exercise May Mitigate Doxorubicin-related Cardiotoxicity
- FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Does Education Level Predict PSA Screening and Prostate Cancer Survival?
- Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia
- Minimal Residual Disease and Patient Genotype May Inform Relapse Risk Algorithms in ALL